Topical microbicides to prevent HIV: Clinical drug development challenges

Research output: Contribution to journalArticle

Abstract

Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.

Original languageEnglish (US)
Pages (from-to)349-375
Number of pages27
JournalAnnual Review of Pharmacology and Toxicology
Volume49
DOIs
StatePublished - 2009

Fingerprint

Local Anti-Infective Agents
Anti-Infective Agents
HIV
Viruses
Pharmaceutical Preparations
Sexual Partners
HIV Infections

Keywords

  • Adverse events
  • Antiretroviral drugs
  • Clinical trial simulation
  • Pharmacodynamics
  • Pharmacokinetics
  • Pre-exposure prophylaxis

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Topical microbicides to prevent HIV : Clinical drug development challenges. / Hendrix, Craig; Ying, Jun Cao; Fuchs, Edward.

In: Annual Review of Pharmacology and Toxicology, Vol. 49, 2009, p. 349-375.

Research output: Contribution to journalArticle

@article{c1dbbe6079db4c8380fe07eefd8e6f8b,
title = "Topical microbicides to prevent HIV: Clinical drug development challenges",
abstract = "Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.",
keywords = "Adverse events, Antiretroviral drugs, Clinical trial simulation, Pharmacodynamics, Pharmacokinetics, Pre-exposure prophylaxis",
author = "Craig Hendrix and Ying, {Jun Cao} and Edward Fuchs",
year = "2009",
doi = "10.1146/annurev.pharmtox.48.113006.094906",
language = "English (US)",
volume = "49",
pages = "349--375",
journal = "Annual Review of Pharmacology and Toxicology",
issn = "0362-1642",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Topical microbicides to prevent HIV

T2 - Clinical drug development challenges

AU - Hendrix, Craig

AU - Ying, Jun Cao

AU - Fuchs, Edward

PY - 2009

Y1 - 2009

N2 - Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.

AB - Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.

KW - Adverse events

KW - Antiretroviral drugs

KW - Clinical trial simulation

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Pre-exposure prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=65249168098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249168098&partnerID=8YFLogxK

U2 - 10.1146/annurev.pharmtox.48.113006.094906

DO - 10.1146/annurev.pharmtox.48.113006.094906

M3 - Article

C2 - 19006450

AN - SCOPUS:65249168098

VL - 49

SP - 349

EP - 375

JO - Annual Review of Pharmacology and Toxicology

JF - Annual Review of Pharmacology and Toxicology

SN - 0362-1642

ER -